Compare Hims and Hers Health Inc (HIMS) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Palantir Technologies Inc — how do they compare? Hims and Hers Health Inc trades at $30.58 (market cap $7.35B), while Palantir Technologies Inc trades at $172.53 (market cap $421.09B). The key difference: Palantir Technologies Inc is far larger — about 57.3× Hims and Hers Health Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| HIMS | PLTR | |
|---|---|---|
Market Cap | $7.35B | $421.09B |
Sector | Health | Technology |
52-Week High | $62.76 | $207.18 |
52-Week Low | $14.52 | $107.27 |
Enterprise Value | $7.73B | $411.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
Palantir (PLTR) trades at $172.01, up 10.32% in 24 hours and near its 52-week high, with bullish technical signals from moving averages. The company reported strong Q2 2026 earnings, beating estimates with 93% revenue growth and a 55% net income margin, while raising full-year guidance. Analyst consensus is a Buy with a $213.44 price target, reflecting optimism around AI-driven commercial expansion.
Outlook remains positive due to accelerating revenue and robust profitability, but high valuation multiples (P/E of 147.02) pose a risk if growth slows. Key opportunities include the $13.1 billion deal backlog and U.S. commercial segment growth, while risks involve competition and execution challenges in sustaining AI adoption momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
